Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Eplerenone for NYHA functional class III/ IV heart failure and left-ventricular systolic dysfunction: clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions One health technology assessment and one systematic review were identified regarding the clinical and cost-effectiveness of eplerenone for patients with New-York Heart Association (NYHA) functional class (FC) III and IV heart failure (HF) and impaired ejection fraction (EF)/left-ventricular systolic dysfunction (LVSD). Indexing Status Subject indexing assigned by CRD MeSH Heart Failure; Heart Failure, Systolic; Humans; Hypertrophy, Left Ventricular; Spironolactone Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000231 Date abstract record published 05/03/2015 |
